Clinical Trial Results: Impact of Bosutinib on Safety, Tolerability, Biomarkers and Clinical Outcomes in Dementia With Lewy Bodies [Phase 2]

View source ↗

Summary

Phase 2 trial assessing bosutinib for safety, tolerability, biomarkers, and clinical outcomes in dementia with Lewy bodies.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dementia with Lewy Bodies

Drugs mentioned

• Bosutinib (bosutinib)

Snippet

Sponsor: Georgetown University | Conditions: Dementia With Lewy Bodies | Phase 2 | Status: COMPLETED | Results posted: 2026-07-10